Clincosm LogoSign in Get a demo

refractory melanoma

Showing 1 - 10 of 10
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Metastatic, Pancreatic Cancer, NSCLC, Metastatic Trial in Denver, Grand Rapids (ST316)

Not yet recruiting
  • Breast Cancer Metastatic
  • +7 more
  • Denver, Colorado
  • +1 more
Apr 28, 2023

Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma Trial in

Not yet recruiting
  • Clinical Stage III Cutaneous Melanoma AJCC v8
  • +4 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Feb 28, 2023

Malignant Solid Tumor, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Ectomesenchymoma Trial in Puerto Rico, United States

Recruiting
  • Malignant Solid Neoplasm
  • +40 more
  • Biospecimen Collection
  • +6 more
  • Birmingham, Alabama
  • +172 more
Jan 27, 2023

Metastatic Melanoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Hodgkin Lymphoma Trial in

Active, not recruiting
Has Results
  • Metastatic Melanoma
  • +22 more
  • Ipilimumab
  • +3 more
  • Birmingham, Alabama
  • +24 more
Jan 19, 2023

Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor Trial in Canada,

Active, not recruiting
  • Clinical Stage IV Cutaneous Melanoma AJCC v8
  • +20 more
  • Pembrolizumab
  • Ziv-Aflibercept
  • Tampa, Florida
  • +8 more
Jan 3, 2023

HLA-A2 Positive Cells Present, Refractory Melanoma Trial in Buffalo (Alpha-type-1 Polarized Dendritic Cells, Celecoxib, PD-1

Recruiting
  • HLA-A2 Positive Cells Present
  • Refractory Melanoma
  • Alpha-type-1 Polarized Dendritic Cells
  • +5 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Dec 12, 2022

Advanced Melanoma, Melanoma of Unknown Primary, Mucosal Melanoma Trial in United States (Ipilimumab, Nivolumab)

Active, not recruiting
  • Advanced Melanoma
  • +10 more
  • Ipilimumab
  • Nivolumab
  • Anchorage, Alaska
  • +638 more
Aug 30, 2022

NSCLC, Metastatic Colorectal Carcinoma, Refractory Melanoma Trial in Pittsburgh (Pixatimod, Nivolumab, Cyclophosphamide (low

Recruiting
  • NSCLC
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Mar 28, 2022

Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Tumor Trial in Houston

Recruiting
  • Advanced Endometrial Carcinoma
  • +36 more
  • Glutaminase Inhibitor IPN60090
  • Pembrolizumab
  • Houston, Texas
    M D Anderson Cancer Center
Sep 9, 2021

Refractory Melanoma Trial in Worldwide (CP-675,206)

Completed
  • Refractory Melanoma
  • Scottsdale, Arizona
  • +64 more
Jun 5, 2012